-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Assumes Biogen at Neutral, Raises Price Target to $185

Benzinga·01/07/2026 13:49:02
语音播报
UBS analyst Michael Yee assumes Biogen (NASDAQ:BIIB) with a Neutral rating and raises Price Target to $185.